Skip to content

Thippili Rasayanam for Childhood Asthma: A Safety and Efficacy Study

Preclinical and Clinical evaluation of the Safety and efficacy of Thippili Rasayanam in the treatment of Iraippu Noi (Childhood Asthma) in children. - TPRFCA-Thippili Rasayanams for Childhood Asthma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090826
Enrollment
40
Registered
2025-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Thippili Rasayanam: Thippili Rasayanam formulation (herbal medicine) for Childhood asthma administered orally for 40 days. Intervention2: Thippili Rasayanam: Thippili Rasayanam formulat

Sponsors

National institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children aged 6 years and 12 years old at time of giving consent 2. Children with symptoms of Wheezing, Cough, difficulty in breathing, Tightness of Chest as per IAP 2022 Asthma guidelines 3. History of wheezing more than three episodes in a year. 4. Patients having Spirometry values within ranges [FEV1] 5. Willing to sign consent and assent forms. 6. Patient willing to attend the OPD once in 7 days for 40 days.

Exclusion criteria

Exclusion criteria: 1. Any other lung disease other than Asthma. 2. Patients unable to perform Spirometry test. 3. Patients who are in the process of another clinical research. 4. Children with any other active systemic illnesses

Design outcomes

Primary

MeasureTime frame
Efficacy of the trial drug is measured by Spirometry test (FEV1) on 0th,22th and 40th day treatment and improvement in the clinical condition will be determined through in this data. Changes in the clinical symptoms will be recorded by Asthma control Questionnaire at each visit (Once in 7 days) for 40 days. Timepoint: Pre-treatment, post-treatment (40 days), and follow-up (3 months).

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactKSuresh

National Institute of Siddha

drsureshherbal@gmail.com9962571137

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026